Agenus posts third quarter 2026 results and advances Phase 3 ROBBIN and BOT plus BAL approvals

Agenus posts third quarter 2026 results and advances Phase 3 ROBBIN and BOT plus BAL approvals
Agenus Q3 2026 results, BOT BAL news

Agenus reported its financial results for the third quarter of 2026, noting ongoing progress toward commencing Phase 3 clinical trials for the ROBBIN program.

The company also announced new clinical evidence from its NEST and UNICORN projects and the receipt of the first BOT plus BAL marketing authorizations in Armenia.

In its recent Phase 2 trial for dMMR colon cancer, Agenus reported a 72 percent pathologic complete response and 83 percent major pathologic response rates, according to previous disclosures. The company had also announced plans to release its third quarter 2026 financial results on November 5, ahead of the U.S. market open, as detailed in a prior statement. These updates follow a series of clinical and regulatory developments for the firm.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.